Martin L. Lee
Martin L. Lee, Ph.D.
Dr. Martin L. Lee has spent more than 45 years in the pharmaceutical, medical device, biotech and nutraceutical industries. In those years, he has been head of clinical research, regulatory affairs, quality control and biostatistics. He has reached levels of Director, Vice President and Senior Vice President. During his tenure, Dr. Lee has overseen landmark achievements in various medical fields, including the introduction of the first immunotherapeutic for Guillain-Barre Syndrome, the first recombinant DNA-produced Factor VIII preparation for individuals with hemophilia A, the first completely human milk-based fortifier for extremely premature infants, and a fibrinogen/ thrombin based surgical adhesive for the treatment of severe burns and the promotion of wound healing. In addition, his work has involved the study of novel therapeutic biologics for the treatment of chronic lymphocytic leukemia, multiple myeloma, SLE, rheumatoid arthritis, Type 1 and 2 diabetes, hemophilia B and other rare bleeding disorders, and Stage 4 melanoma. Dr. Lee has also spent much of that tenure in academia performing clinical research into topics such as smoking cessation, PTSD in veterans, improved methods for the delivery of primary care at the Veterans Administration (VA), and treatment for depression and betters ways to identify individuals at risk.
Dr. Lee is an Adjunct Professor of Biostatistics in the Fielding School of Public Health at the University of California, Los Angeles, and Professor of Internal Medicine at the Charles R. Drew University of Science and Medicine. He is the author or co-author of over 275 scientific papers, and is a Fellow of the Royal Statistical Society. Dr. Lee is a Chartered Statistician and a Chartered Scientist as designated by the Royal Statistical Society and a Fellow of the Institute of Biomedical Sciences. Dr. Lee received a B.A. in mathematics, and M.S. and Ph.D. degrees in biostatistics with a minor in biological chemistry from the University of California, Los Angeles.